MA51681A - Anticorps humains contre l'hémagglutinine de la grippe - Google Patents
Anticorps humains contre l'hémagglutinine de la grippeInfo
- Publication number
- MA51681A MA51681A MA051681A MA51681A MA51681A MA 51681 A MA51681 A MA 51681A MA 051681 A MA051681 A MA 051681A MA 51681 A MA51681 A MA 51681A MA 51681 A MA51681 A MA 51681A
- Authority
- MA
- Morocco
- Prior art keywords
- human antibodies
- antibodies against
- influenza hemagglutinin
- against influenza
- hemagglutinin
- Prior art date
Links
- 101710154606 Hemagglutinin Proteins 0.000 title 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 title 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 title 1
- 101710176177 Protein A56 Proteins 0.000 title 1
- 239000000185 hemagglutinin Substances 0.000 title 1
- 206010022000 influenza Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622480P | 2018-01-26 | 2018-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51681A true MA51681A (fr) | 2021-05-05 |
Family
ID=66286952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051681A MA51681A (fr) | 2018-01-26 | 2019-01-24 | Anticorps humains contre l'hémagglutinine de la grippe |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11780907B2 (fr) |
| EP (1) | EP3743442A1 (fr) |
| JP (2) | JP7372925B2 (fr) |
| KR (1) | KR20200115517A (fr) |
| CN (1) | CN111670195A (fr) |
| AU (1) | AU2019212480A1 (fr) |
| BR (1) | BR112020014849A2 (fr) |
| CA (1) | CA3088194A1 (fr) |
| CL (1) | CL2020001884A1 (fr) |
| CO (1) | CO2020009043A2 (fr) |
| EA (1) | EA202091563A1 (fr) |
| IL (1) | IL275884A (fr) |
| MA (1) | MA51681A (fr) |
| MX (1) | MX2020007772A (fr) |
| PH (1) | PH12020551051A1 (fr) |
| SG (1) | SG11202006379UA (fr) |
| WO (1) | WO2019147867A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230107644A1 (en) * | 2020-04-01 | 2023-04-06 | University Of Rochester | Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses |
| IL302938A (en) * | 2020-11-23 | 2023-07-01 | Vir Biotechnology Inc | Antibodies against influenza A viruses |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (fr) | 2004-04-20 | 2005-11-03 | Genmab A/S | Anticorps monoclonaux humains diriges contre cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| EP1885860A2 (fr) * | 2005-05-16 | 2008-02-13 | Morphotek, Inc. | Vecteurs regules pour la selection de cellules presentnant des phenotypes specifiques |
| RS52643B (en) | 2006-06-02 | 2013-06-28 | Regeneron Pharmaceuticals Inc. | HIGH AFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR |
| JP5161882B2 (ja) | 2006-09-07 | 2013-03-13 | クルセル ホランド ベー ヴェー | インフルエンザウイルスｈ５ｎ１を中和しうるヒト結合性分子およびその使用 |
| EP1947423A1 (fr) | 2007-01-16 | 2008-07-23 | Sony Deutschland Gmbh | Contrôleur sensible à la distance, à l'orientation et à la vitesse |
| CN101687921A (zh) | 2007-05-11 | 2010-03-31 | 淡马锡生命科学研究院有限公司 | 可用于h5禽流感诊断和监视的h5亚型特异性结合蛋白 |
| CN101883789B (zh) | 2007-09-13 | 2014-10-08 | 淡马锡生命科学研究院有限公司 | 特异于流感病毒h5亚型或者n1亚型的血凝素和神经氨酸酶的单克隆抗体及其应用 |
| AU2008297586B2 (en) | 2007-09-13 | 2013-06-20 | National Institute Of Health Research And Development (Nihrd)- Ministry Of Health Of The Republic Of Indonesia | Monoclonal antibodies specific to hemagglutinin from influenza virus H5-subtype and uses thereof |
| US20110038935A1 (en) | 2007-12-06 | 2011-02-17 | Marasco Wayne A | Antibodies against influenza virus and methods of use thereof |
| WO2009099394A1 (fr) | 2008-02-05 | 2009-08-13 | Temasek Life Sciences Laboratory Limited | Protéine de liaison et elisa de blocage d'épitope pour la détection universelle de virus de la grippe de sous-type h5 |
| EP2698380A1 (fr) | 2008-03-28 | 2014-02-19 | Sea Lane Biotechnologies, LLC | Neutralisation de molécules pour antigènes viraux |
| NZ590890A (en) | 2008-07-25 | 2013-05-31 | Inst Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| EP2328928A2 (fr) | 2008-08-25 | 2011-06-08 | Dana-Farber Cancer Institute, Inc. | Epitope conservé d'hémagglutinine, anticorps contre l'épitope et procédés d'utilisation |
| WO2010074656A1 (fr) | 2008-12-24 | 2010-07-01 | Temasek Life Sciences Laboratory Limited | Anticorps monoclonaux spécifiques du peptide de fusion de l'hémagglutine issu des virus influenza a et leurs applications |
| US8975378B2 (en) | 2008-12-25 | 2015-03-10 | Osaka University | Human anti-human influenza virus antibody |
| CN102448986B (zh) | 2009-05-11 | 2015-11-25 | 克鲁塞尔荷兰公司 | 能中和流感病毒h3n2的人结合分子及其应用 |
| AU2010249046A1 (en) | 2009-05-13 | 2011-12-01 | Sea Lane Biotechnologies, Llc | Neutralizing molecules to influenza viruses |
| PL2975051T3 (pl) | 2009-06-26 | 2021-09-20 | Regeneron Pharmaceuticals, Inc. | Wyizolowane z łatwością dwuswoiste przeciwciała o formacie natywnej immunoglobuliny |
| TR201906650T4 (tr) | 2010-02-08 | 2019-05-21 | Regeneron Pharma | Ortak hafif zincirli fare. |
| AU2011225044B2 (en) | 2010-03-08 | 2013-08-22 | Celltrion, Inc. | Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses |
| AU2011268072C1 (en) | 2010-06-17 | 2017-10-19 | Trellis Bioscience, Llc | Antibodies useful in passive influenza immunization |
| US9534042B2 (en) | 2010-09-03 | 2017-01-03 | Fujita Health University | Influenza virus-neutralizing antibody and screening method therefor |
| WO2012045001A2 (fr) | 2010-09-30 | 2012-04-05 | Vanderbilt University | Anticorps dirigés contre le virus de la grippe, immunogènes et leurs utilisations |
| AU2012282504B2 (en) | 2011-07-14 | 2017-07-20 | Janssen Vaccines & Prevention B.V. | Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses |
| ITRM20110606A1 (it) | 2011-11-16 | 2013-05-17 | Ist Superiore Sanita | Peptidi della lattoferrina per lo uso come inibitori ad ampio spettro dellainfezione da virus della influenza. |
| JP6325451B2 (ja) | 2011-12-02 | 2018-05-16 | アイム・セラピューティクス・べー・フェー | Ａ型インフルエンザに特異的な抗体 |
| CN104302321A (zh) | 2011-12-05 | 2015-01-21 | 特瑞利斯生物科学有限责任公司 | 可用于被动流感免疫的抗体 |
| US8834881B2 (en) | 2012-03-08 | 2014-09-16 | Crucell Holland B.V. | Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| ES2701746T3 (es) * | 2012-11-13 | 2019-02-25 | Hoffmann La Roche | Anticuerpos antihemaglutinina y procedimientos de uso |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| KR20140118682A (ko) | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물 |
| SG11201602522VA (en) | 2013-10-02 | 2016-04-28 | Medimmune Llc | Neutralizing anti-influenza a antibodies and uses thereof |
| JP6712428B2 (ja) | 2014-02-04 | 2020-06-24 | コントラフェクト コーポレイション | インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法 |
| AU2015235983A1 (en) | 2014-03-27 | 2016-10-06 | Genentech, Inc. | Anti-influenza B virus hemagglutinin antibodies and methods of use |
| CN104031118B (zh) | 2014-06-19 | 2016-04-13 | 天津大学 | 鼠多瘤病毒衣壳粒的新型亲和肽配基及其设计筛选方法 |
| TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| US10435462B2 (en) | 2015-03-31 | 2019-10-08 | Viro Dynamics Corporation | Hybrid influenza seed viruses, compositions thereof, and use thereof in the diagnosis or therapy of influenza |
| CN107750253B (zh) | 2015-04-08 | 2022-10-04 | 达纳－法伯癌症研究所公司 | 人源化流感单克隆抗体及其使用方法 |
| US10442854B2 (en) | 2015-06-01 | 2019-10-15 | Medimmune, Llc | Neutralizing anti-influenza binding molecules and uses thereof |
| WO2017192589A1 (fr) | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticorps neutralisants dirigés contre la grippe ha, leur utilisation et leur identification |
| WO2020221450A1 (fr) | 2019-04-30 | 2020-11-05 | Humabs Biomed Sa | Anticorps et méthodes de traitement d'une infection par la grippe a |
-
2019
- 2019-01-24 MA MA051681A patent/MA51681A/fr unknown
- 2019-01-24 MX MX2020007772A patent/MX2020007772A/es unknown
- 2019-01-24 AU AU2019212480A patent/AU2019212480A1/en active Pending
- 2019-01-24 JP JP2020539709A patent/JP7372925B2/ja active Active
- 2019-01-24 US US16/964,579 patent/US11780907B2/en active Active
- 2019-01-24 CN CN201980009873.XA patent/CN111670195A/zh active Pending
- 2019-01-24 EA EA202091563A patent/EA202091563A1/ru unknown
- 2019-01-24 CA CA3088194A patent/CA3088194A1/fr active Pending
- 2019-01-24 KR KR1020207022064A patent/KR20200115517A/ko active Search and Examination
- 2019-01-24 WO PCT/US2019/015029 patent/WO2019147867A1/fr unknown
- 2019-01-24 SG SG11202006379UA patent/SG11202006379UA/en unknown
- 2019-01-24 EP EP19719656.1A patent/EP3743442A1/fr active Pending
- 2019-01-24 BR BR112020014849-0A patent/BR112020014849A2/pt unknown
-
2020
- 2020-07-06 IL IL275884A patent/IL275884A/en unknown
- 2020-07-07 PH PH12020551051A patent/PH12020551051A1/en unknown
- 2020-07-17 CL CL2020001884A patent/CL2020001884A1/es unknown
- 2020-07-23 CO CONC2020/0009043A patent/CO2020009043A2/es unknown
-
2023
- 2023-02-28 JP JP2023030129A patent/JP2023060018A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA202091563A1 (ru) | 2020-10-08 |
| MX2020007772A (es) | 2020-09-18 |
| CL2020001884A1 (es) | 2020-12-11 |
| CN111670195A (zh) | 2020-09-15 |
| CA3088194A1 (fr) | 2019-08-01 |
| US11780907B2 (en) | 2023-10-10 |
| EP3743442A1 (fr) | 2020-12-02 |
| WO2019147867A9 (fr) | 2019-11-07 |
| PH12020551051A1 (en) | 2021-08-23 |
| AU2019212480A1 (en) | 2020-09-10 |
| IL275884A (en) | 2020-08-31 |
| WO2019147867A1 (fr) | 2019-08-01 |
| US20210371505A1 (en) | 2021-12-02 |
| KR20200115517A (ko) | 2020-10-07 |
| CO2020009043A2 (es) | 2020-07-31 |
| JP7372925B2 (ja) | 2023-11-01 |
| JP2021511043A (ja) | 2021-05-06 |
| JP2023060018A (ja) | 2023-04-27 |
| BR112020014849A2 (pt) | 2020-12-08 |
| SG11202006379UA (en) | 2020-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49043A (fr) | Formulation stable d'anticorps | |
| MA43108A (fr) | Anticorps neutralisant le virus syncytial respiratoire humain | |
| MA41937A (fr) | Conjugués de médicaments comprenant des anticorps contre la claudine 18.2 | |
| MA44077A (fr) | Anticorps neutralisants le virus de l'immunodéficience humaine | |
| MA52884A (fr) | Anticorps anti-il-11 | |
| MA46820A (fr) | Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques | |
| MA54052A (fr) | Formulation d'anticorps | |
| MA54139A (fr) | Formulation d'anticorps | |
| MA52152A (fr) | Anticorps | |
| MA44236A (fr) | Anticorps anti-tgfbêta 2 | |
| MA43112A (fr) | Pulvérisateur d'aérosol aseptique de dose unitaire | |
| MA50654A (fr) | Anticorps anti-pacap | |
| MA53466A (fr) | Formulation stable d'anticorps anti-osmr | |
| MA56466A (fr) | Anticorps anti-epha4 | |
| MA51681A (fr) | Anticorps humains contre l'hémagglutinine de la grippe | |
| MA55033A (fr) | Formulation d'anticorps thérapeutique | |
| MA47106A (fr) | Formulations d'anticorps anti-tnf alpha | |
| MA49257A (fr) | Anticorps anti-trkb | |
| MA54097A (fr) | Anticorps anti-fn14 humain | |
| MA50156A (fr) | Variants d'anticorps | |
| MA54095A (fr) | Formulations pharmaceutiques aqueuses | |
| MA46642A (fr) | Promédicaments d'inhibiteurs de la kallicréine | |
| MA45159A (fr) | Polypeptides d'hémagglutinine d'influenza modifiés | |
| MA56394A (fr) | Anticorps anti-angpt2 | |
| MA55519A (fr) | Anticorps anti-fgf23 |